Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $388.4 million.

  • Neurocrine Biosciences' Cash from Operations rose 6016.49% to $388.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $782.7 million, marking a year-over-year increase of 3145.78%. This contributed to the annual value of $782.7 million for FY2025, which is 3145.78% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Cash from Operations stood at $388.4 million, which was up 6016.49% from $227.5 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Cash from Operations ranged from a high of $388.4 million in Q4 2025 and a low of -$125.2 million during Q1 2023
  • Its 4-year average for Cash from Operations is $142.7 million, with a median of $130.3 million in 2024.
  • Examining YoY changes over the last 5 years, Neurocrine Biosciences' Cash from Operations showed a top increase of 20407.35% in 2024 and a maximum decrease of 6403.12% in 2024.
  • Neurocrine Biosciences' Cash from Operations (Quarter) stood at $87.3 million in 2021, then surged by 41.47% to $123.5 million in 2023, then surged by 96.36% to $242.5 million in 2024, then soared by 60.16% to $388.4 million in 2025.
  • Its Cash from Operations stands at $388.4 million for Q4 2025, versus $227.5 million for Q3 2025 and $102.0 million for Q2 2025.